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One of the main mechanisms of messenger RNA degradation in
eukaryotes occurs by deadenylation-dependent decapping which
leads to 59-to-39 decay1,2. A family of Sm-like (Lsm) proteins has
been identi®ed, members of which contain the `Sm' sequence
motif, form a complex with U6 small nuclear RNA and are
required for pre-mRNA splicing3±9. Here we show that mutations
in seven yeast Lsm proteins (Lsm1±Lsm7) also lead to inhibition
of mRNA decapping. In addition, the Lsm1±Lsm7 proteins co-
immunoprecipitate with the mRNA decapping enzyme (Dcp1), a
decapping activator (Pat1/Mrt1) and with mRNA. This indicates
that the Lsm proteins may promote decapping by interactions
with the mRNA and the decapping machinery. In addition, the
Lsm complex that functions in mRNA decay appears to be distinct
from the U6-associated Lsm complex, indicating that Lsm pro-
teins form speci®c complexes that affect different aspects of
mRNA metabolism.
We proposed that the family of Lsm proteins affects mRNA
degradation because lsm1 strains are de®cient in mRNA decapping10
and the Lsm proteins interact with each other6,7. Thus, we examined
the decay of the MFA2pG and PGK1pG reporter mRNAs11 in strains
with the nonessential LSM1, LSM6 or LSM7 genes (each of which is
thermosensitive) deleted, and in strains carrying temperature-
sensitive forms of LSM2 or LSM5, or a partial loss-of-function
allele of LSM8. The reporter mRNAs are under the control of the
GAL1 UAS to allow measurement of their decay rates and contain a
poly(G) tract in their 39 untranslated region (UTR), which traps
decay intermediates by blocking the 59-to-39 exonuclease in cis12,13.
Mutations inhibiting mRNA turnover accumulate full-length
mRNA and show a decrease in the levels of the decay intermediate12.
Two observations indicated that loss-of-function alleles of
LSM1±LSM7 inhibited mRNA degradation. First, loss-of-function
alleles in the LSM1, LSM2, LSM5, LSM6 and LSM7 genes led to
increased levels of full-length mRNA and decreased levels of decay
intermediate for both the MFA2pG (Fig. 1, in 0 min) and PGK1pG
(data not shown) transcripts. Second, the MFA2pG transcript
showed a slower decay rate (Fig. 1) in the lsm1, lsm2, lsm5, lsm6
and lsm7 mutant strains as compared with wild-type strains.
Although the lsm1, lsm2, lsm5, lsm6 and lsm7 alleles cause thermo-
sensitive growth, we observed the effects on mRNA decay at both
24 8C (Fig. 1) and 37 8C (data not shown). The lsm8-1 allele
examined did not affect mRNA turnover. The inactivation of the
Lsm proteins caused a partial defect in mRNA decay as compared
with the complete block seen in dcp1¢ and dcp2¢ strains14,15,
suggesting that Lsm proteins activate mRNA decay. Consistent
with this view, an lsm1¢ lsm6¢ double mutant strain did not
show an increased defect in mRNA decay (Fig. 1).
To determine which step in mRNA degradation was affected in
the lsm mutants, we examined the structure of the MFA2pG mRNA
in these strains. Strains de®cient in decapping or in 59-to-39
exonucleolysis accumulate oligoadenylated, full-length mRNA
species, with or without cap, respectively10,12,14±16. Thus, we
examined the poly(A) distribution on the MFA2pG mRNA in the
lsm mutants with or without fractionation into capped and
uncapped fractions by immunoprecipitation with anti-cap antibo-
dies. Strains mutant in LSM1±LSM7 accumulated MFA2pG tran-
scripts with short poly(A) tails (Fig. 2, T lanes), indicating that these
strains were de®cient in decapping or in 59-to-39 exonucleolysis. A
substantial amount of the accumulated oligoadenylated species in
the lsm1, lsm2, lsm5, lsm6 and lsm7 strains was immunoprecipitated
by antisera against the cap structure, similar to the dcp1¢ strain,
wherein decapping is blocked (Fig. 2). This indicated that LSM2,
LSM5, LSM6 and LSM7 are required, as is LSM1 (ref. 10) for
ef®cient mRNA decapping. Moreover, in strains where the only
copy of the essential LSM3 or LSM4 is expressed from a GAL
promoter, transfer of the culture to glucose medium (thereby
depleting Lsm3 or Lsm4 (ref. 7) led to the accumulation of
capped, deadenylated MFA2pG mRNAs (Fig. 2). This observation,
together with the co-immunoprecipitation of Lsm3 and Lsm4 with
mRNA decay factors (see below), suggests that LSM3 and LSM4 are
also required for ef®cient mRNA decapping.
Two-hybrid analysis has identi®ed interactions between Lsm
proteins and the Dcp1 decapping enzyme, the Xrn1 59-to-39
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Figure 1 MFA2pG mRNA is stabilized in most lsm mutant strains. The decay of the
MFA2pG transcript after repression of transcription by the addition of glucose in lsm
mutants and wild-type (WT) strain at 24 8C is shown. The top band is the full-length mRNA
and the lower band is the mRNA fragment produced by 59-to-39 exonucleolytic digestion
to the 59 side of the poly(G) tract11. The strains used were WT (yRP841), lsm1¢
(yRP1365), lsm2ts (yRP1366), lsm5ts (yRP1367), lsm6¢ (yRP1369), lsm7¢ (yRP1370),
lsm8-1(BP4), pat1/mrt1¢ (yRP1372) and lsm1¢ lsm6¢(yRP1407).
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two-hybrid interactions with Pat1 (YCR077c)17, a protein originally
identi®ed through a two-hybrid interaction with topoisomerase II
(ref. 18). Pat1¢ strains have multiple phenotypes, including tem-
perature sensitivity, that are similar to mutations in the MRT1 gene,
an uncloned locus known to affect mRNA decapping12. There is
evidence that MRT1 and PAT1 are the same gene. First, the PAT1
gene complements the temperature sensitivity and mRNA decay
defect in mrt1 strains (data not shown). Second, pat1¢ strains show
a defect in mRNA decay similar to the mrt1 alleles (Fig. 1). Third,
sequencing of the PAT1 gene from strains carrying the mrt1-1, mrt1-
2 and mrt1-3 alleles identi®ed mutations creating nonsense codons
at amino acids 547, 157 and 308, respectively. Fourth, the mrt1
alleles and the pat1¢ are genetically linked and pat1¢ fails to
complement the mrt1 lesions in diploids (data not shown). Thus,
PAT1/MRT1 is required for ef®cient mRNA decapping.
To investigate the signi®cance of the two-hybrid interactions
between the Lsm proteins and the proteins required for mRNA
decapping, we immunoprecipitated epitope-tagged proteins Lsm1±
Lsm8 and determined whether Dcp1 or Pat1/Mrt1 co-immuno-
precipitated by using western analysis. Dcp1 co-immuno-
precipitated with Lsm1±Lsm7, although the ef®ciency of co-
immunoprecipitation varied (Fig. 3a). No co-immunoprecipitation
of Dcp1 with Lsm8 could be detected, however, even after long
exposures. Similarly, Pat1/Mrt1 also co-immunoprecipitates with
Lsm1±Lsm7 proteins, but not with Lsm8 (Fig. 3b; and data not
shown).
The Lsm and Sm proteins are RNA-binding complexes and
function in splicing by assembling with snRNAs3,4. To investigate
whether Lsm proteins affect decapping through interactions with
mRNA, we determined whether mRNAs co-immunoprecipitated
with Lsm proteins (Fig. 4). Lsm1, Lsm5 and Dcp1 co-immuno-
precipitated with a small (1±3% of the total) but clearly detectable
amount of CYH2 mRNA. In contrast, Lsm8 did not co-immuno-
precipitate the CYH2 mRNA in amounts signi®cantly above back-
ground levels. Moreover, we did not detect U6 snRNA in
immunoprecipitates of Lsm1 and Dcp1, which indicates that
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Figure 2 Lsm mutants accumulate oligoadenylated, full-length capped mRNAs. Steady-
state mRNA from various lsm mutants, dcp1¢, xrn1¢ and wild-type strains were
analysed on a polyacrylamide northern blot with or without immunoprecipitation with anti-
cap antibodies. Strains expressing LSM3 and LSM4 under GAL control were shifted to
glucose for 12 h before analysis, which has been shown to deplete these proteins7. T, total
RNA; P, RNA extracted from the immunoprecipitate; S, supernatant. Radiolabelled HpaII-















































































































Figure 3 Lsm proteins co-immunoprecipitate with proteins involved in mRNA decay.
a, Dcp1 co-immunoprecipitates with proteins Lsm1±Lsm7. Epitope-tagged Lsm proteins
were immunoprecipitated and the immunoprecipitates were analysed by western blot for
Dcp1. b, Co-immunoprecipitation of Pat1 with HA-tagged Lsm proteins. Epitope-tagged
Lsm proteins were immunoprecipitated and the immunoprecipitates were analysed by
western blot for Pat1. Isy1, a protein involved in pre-mRNA splicing22, was used as a
control. c, Interaction between Dcp1 and Lsm proteins is RNA dependent. Immuno-
precipitation of Dcp1 (right panel) and HA±Lsm5 (left panel) from lysates of different
strains (indicated above the lanes) was done with (`+RNase') or without prior RNase
treatment and presence of co-immunoprecipitating proteins (Dcp1 and Lsm1) was
analysed by western blot using polyclonal Dcp1 or Lsm1 antisera.
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these interactions are RNA speci®c (Fig. 4b; and data not shown).
These results suggest that Lsm proteins interact with mRNA mol-
ecules and thereby modulate decapping. The co-immuno-
precipitation of Lsm proteins with Dcp1, but not with each other
or Pat1, is sensitive to RNase treatment (Fig. 3c and data not
shown). This suggests that either the Lsm complex and Dcp1
interact directly in a manner dependent on one or both of these
proteins binding mRNA, or that these proteins interact simulta-
neously with the same mRNA molecules. Thus, the co-immuno-
precipitation of Lsm proteins, Dcp1 and mRNA may re¯ect the
detection of a transient mRNP (ribonuclear protein particle)
organization that exists before mRNA decapping.
These physical interactions suggest that the Lsm proteins have a
role in cytoplasmic mRNA degradation. Consistent with this view,
Lsm1, Lsm7, Dcp1 and Pat1 can be detected in the cytoplasm by
immuno¯uorescence (Fig. 5). Lsm7 was also found in both com-
partments, consistent with it affecting both mRNA decay and
splicing6,7. Some nuclear staining was observed for both Dcp1 and
Lsm1, suggesting that these proteins may also have a nuclear
function.
Several observations indicate that a complex, consisting of Lsm1±
Lsm7, is involved in mRNA decay and that a different complex,
consisting of Lsm2±Lsm8, is associated with U6 and involved in
pre-mRNA splicing. First, although mutations in LSM2±LSM7
affect both mRNA decay and pre-mRNA splicing, mutations in
LSM1 only affect mRNA decay, and lesions in LSM8 affect splicing
but not mRNA decay (Fig. 1)7,8,10. Second, proteins Lsm2±Lsm7 co-
immunoprecipitate with both U6 snRNA6,7,9 and mRNA decay
factors (Fig. 3), whereas Lsm1 does not immunoprecipitate U6
snRNA6,7 but does pull down Dcp1 and Pat1/Mrt1 (Fig. 3). In
contrast, Lsm8 does co-immunoprecipitate U6 snRNA6±9 but does
not pull down Dcp1 or Pat1/Mrt1 (Fig. 3). Third, immunoprecipi-
tation of Lsm8 co-immunoprecipitates Lsm2±Lsm7, but not Lsm1
(ref. 6). Fourth, a pair of distinct complexes, each consisting of seven
members, would be consistent with the known organization of Sm
and Lsm proteins19. This suggests that the Lsm proteins form at least
two distinct complexes that are involved in different aspects of RNA
metabolism.
The function of the Lsm proteins in decapping appears to be
to interact with the mRNA substrate and accelerate decapping,
perhaps by promoting rearrangements in mRNP organization that
lead to dissociation of the cytoplasmic cap-binding complex, which
is an inhibitor of decapping20. A general role for Lsm proteins in
modulating RNP structure in a variety of contexts by affecting
RNA±RNA and/or protein±RNA interactions would be consistent
with the proposal that their function in pre-mRNA splicing is to
facilitate RNP rearrangements during splicing7,21. M
Methods
Yeast strains and plasmids
All strains used for decay analysis were in the genetic background of yRP841 (MATa trp1
ura3-52 leu2-3,112 lys2-201 cup1¢::LEU2(PM))12, except the lsm8-1 allele, which was
compared with an isogenic wild-type control. Each strain and its genotypic difference
from yRP841 are as follows: yRP1365 (lsm1¢::TRP1); yRP1366 (lsm2¢::HIS3 pAEM55
(carrying a protein fusion that confers temperature sensitivity to Lsm2); yRP1367
(his4-539 lsm5¢::TRP1 pRP949 (carrying a protein fusion that confers temperature
sensitivity to Lsm5); yRP1369 (lsm6¢::HIS3); yRP1370 (lsm7¢::HIS3 LYS2); yRP1372
(MATa his4-539 pat1¢::LEU2); yRP1407 (MATa lsm1¢::TRP1 lsm6¢::HIS3); yRP1070
(dcp1¢::URA3)14; yRP884 (xrn1¢::URA3)11; BP4 (ref. 8) (MATa lsm8-1) and its isogenic
wild-type control CY3 (ref. 8) (MATa ura3 lys2 ade2 trp1 his3 leu2). All strains used for
immunoprecipitation, except FLAG±LSM4 strain, were in the same genetic background,
expressing an haemagglutin A (HA)-tagged Lsm protein and compared with isogenic
wild-type strains lacking any epitope tags (BMA64)7. Each strain and its genotypic
difference from BMA64 (ref. 7) (MATatrp1¢1, his3-11, -15, ura3-1, leu2-3, -112, ade2-1,
can-100) are as follows: AEMY30 (trp1-1 his3¢200 lsm2¢::HIS3 pAEM55 (HA±LSM2);
AEMY33 (ref. 7) (trp1-1 his3¢200 lsm2¢::HIS3 pAEM55 (HA±LSM2); AEMY33 (ref. 7)
(lsm3¢::TRP1 pAEM64 (GAL±HA±LSM3)); AEMY28 (ref. 7 (HA±LSM1); AEMY45
(Mata lsm8¢::TRP1 pAEM76 (GAL±HA±LSM8)); AEMY47 (ref. 7) (lsm5¢::TRP1
pAEM75 (GAL±HA±LSM5)). AEMY49 (MATa LSM6±HA±TRP1), AEMY50 (MATa
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Figure 4 Lsm proteins and Dcp1 co-immunoprecipitate mRNA. RNA was extracted from
the immunoprecipitate (P) of Dcp1, HA±Lsm5, HA±Lsm1 or HA-Lsm8 and analysed by
northern blot for CYH2 mRNA (a) or U6 snRNA (b). Similar analysis of aliquots of the lysate
(T), and supernate (S) for the CYH2 mRNA is also shown (a).
Figure 5 Cellular localization of Dcp1, Pat1/Mrt1, Lsm7 and Lsm1 by immuno-
¯uorescence analysis. a±c, Strains expressing HA-tagged Dcp1 (AEMY121 (a)), Lsm7
(AEMY51 (b)) or Lsm1 (AEMY28 (c)) were stained with anti-HA antibodies and anti-rat
(¯uorescein isothiocyanate) secondary antibody (green ¯uorescence, left panel), or
subjected to 4,6-diamidino-2-phenylindole (DAPI) nuclear staining (blue ¯uorescence,
middle panel). A merger of the two panels is shown in the right panel in each case.
d, AEMY54 cells were stained with anti-Pat1 antibodies and anti-rabbit (cy3) secondary
antibody (red ¯uorescence, left panel), or DAPI nuclear stain (blue ¯uorescence, middle
panel). e, As a control, cells expressing the HA-tagged Sme1 nuclear protein (AEMY54)
were stained with anti-HA antibodies and anti-rat (¯uorescein isothiocyanate) secondary
antibody (green ¯uorescence, left panel). A merge of HA±Sme1 staining and Pat1 staining
(middle panel), and a merge of HA±Sme1 staining and DAPI nuclear staining (right panel).
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LSM7±HA±TRP1); IDY2 (ref. 22) (MATa trp1-1 his3¢200 isy1¢::HIS3 pCA23 (HA±ISY1,
CEN URA3)). For Lsm4, the MCY4 (ref. 5) strain expressing GPD promoter-controlled
FLAG±Lsm4 protein from a plasmid (pRP961) was used. This strain has a chromosomal
LSM4 gene under GAL UAS control and was grown in glucose medium for the experiment.
MCY4 (ref. 5) (MATa LEU2±GAL±LSM4) was compared with its isogenic wild-type strain
w303 (MATa ade1-101 his3-¢1 trp1-289 ura33-52) without epitope-tagged proteins.
RNA analysis
Transcriptional shut-off experiments, northern analysis and immunoprecipitation of
RNA were performed as described12,13,15. Oligo oRP140 (59-ATATTGATTAGATCAGG-
AATTCC-39) was used to probe for MFA2pG mRNA.
Immunology
The immunoprecipitation and immuno¯uorescence experiments followed standard
protocols. The HA±Lsm protein immunoprecipitations shown in Fig. 3a and c were done
using anti-HA antibody sepharose. Lysis and washing buffer was IPD1 buffer (50 mM Tris
pH7.5, 50 mM NaCl, 2 mM MgCl2, 0.1% Nonidet P-40) containing 1 mM b-mercap-
toethanol and 1´ `COMPLETE' protease inhibitor mix (Boeringer Manheim). Bound
proteins were eluted with 50 mM Tris pH7.5, 100 mM NaCl, 2 mM MgCl2, 1% SDS,
1 mg ml-1 HA peptide and 1´ COMPLETE protease inhibitor mix, and analysed for
presence of Dcp1 by western blotting23. The Dcp1 immunoprecipitation shown in Fig. 3c
was done similarly using anti-Dcp1 polyclonal antibodies and protein A sepharose, and
the co-immunoprecipitating Lsm1 was revealed in western blots using anti-Lsm1 poly-
clonal antibodies. Elution buffer was as above but without HA peptide. The immuno-
precipitation of FLAG±Lsm4 shown in Fig. 3a was done similarly using anti-FLAG
antibody agarose (Sigma). Lysis was in IPD2 buffer (50 mM Tris pH7.5, 25 mM NaCl,
2 mM MgCl2, 0.2% Nonidet P-40). IPD2 buffer without Nonidet P-40 was used to wash
the beads. Elution buffer was as above but with 200 mg ml-1 FLAG peptide. HA±Lsm
immunoprecipitation in Fig. 3b was done using anti-HA antibodies and protein A
sepharose. Lysis and washing buffer was 6 mM HEPES pH7.9, 150 mM NaCl, 2.5 mM
MgCl2, 0.05% Nonidet P-40. Immunoprecipitated proteins were extracted by boiling
pellets in SDS sample buffer and western analysed using anti-Pat1 polyclonal antibodies.
To study the RNA dependence of co-immunoprecipitations, lysates were treated with
0.5 mg ml-1 RNase A for 10 min at room temperature before preclearing. To study the
co-immunoprecipitation of RNA, total RNA extracted from the immunoprecipitates was
analysed by northern blotting using CYH2 complementary DNA probe or U6 oligo probe
(oRP 759: 59-GACCAAATGTCCACGAAGGG-39).
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The serine proteinase a-thrombin causes blood clotting through
proteolytic cleavage of ®brinogen and protease-activated recep-
tors and ampli®es its own generation by activating the essential
clotting factors V and VIII1. Thrombomodulin2, a transmembrane
thrombin receptor with six contiguous epidermal growth factor-
like domains (TME1±6), profoundly alters the substrate speci®-
city of thrombin from pro- to anticoagulant by activating protein
C (see, for example, reference 2). Activated protein C then
deactivates the coagulation cascade by degrading activated factors
V and VIII2. The thrombin±thrombomodulin complex inhibits
®brinolysis by activating the procarboxypeptidase thrombin-
activatable ®brinolysis inhibitor3. Here we present the 2.3 AÊ
crystal structure of human a-thrombin bound to the smallest
thrombomodulin fragment required for full protein-C co-factor
activity, TME456. The Y-shaped thrombomodulin fragment binds
to thrombin's anion-binding exosite-I, preventing binding of
procoagulant substrates. Thrombomodulin binding does not
seem to induce marked allosteric structural rearrangements at
the thrombin active site. Rather, docking of a protein C model to
thrombin±TME456 indicates that TME45 may bind substrates in
such a manner that their zymogen-activation cleavage sites are
presented optimally to the unaltered thrombin active site.
Thrombomodulin consists of a lectin-like amino-terminal
domain, followed by a hydrophobic segment, six contiguous epi-
dermal growth factor (EGF)-like domains, an O-glycosylated
serine/threonine-rich domain, a transmembrane segment and a
short cytoplasmic tail (Fig. 1a). Upon thrombomodulin binding,
thrombin activation of both protein C and thrombin-activatable
®brinolysis inhibitor (TAFI) is enhanced by at least three orders of
magnitude2,3. Different hypotheses have been proposed to explain
the thrombomodulin-induced switch in thrombin speci®city.
Mutagenesis studies (see, for example, ref. 4) and experiments
with ¯uorescence5 or spin label6 active-site probes indicate that
thrombomodulin binding may cause allosteric changes in the
© 2000 Macmillan Magazines Ltd
